EXACT SCIENCES CORP (EXAS)

EXAS Makes Bullish Cross Above Critical Moving Average

Notable Wednesday Option Activity: FIVE, EXAS, GM

Exact Sciences to Participate in December Investor Conferences

Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024

EXACT Sciences Larger Than S&P 500 Component Marketaxess Holding

Thursday 11/14 Insider Buying Report: LMND, EXAS

Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy

Relative Strength Alert For EXACT Sciences

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?

The company reported lighter-than-expected third-quarter sales due to issues with physician order rates.

Exact Sciences (EXAS) Q3 2024 Earnings Call Transcript

EXAS earnings call for the period ending September 30, 2024.

Exact Sciences Announces Third-Quarter 2024 Results

Noteworthy Tuesday Option Activity: BYD, MQ, EXAS

Exact Sciences to Participate in November Investor Conference

Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement

Can This Beaten-Down Cathie Wood Stock Bounce Back?

An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback.

Exact Sciences Schedules Third Quarter 2024 Earnings Call

Exact Sciences Stock Rises After FDA Signs Off On New Cologuard

The company is soon to launch its next-generation colon cancer screening tool.

FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening

Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024

Noteworthy Thursday Option Activity: CLF, EXAS, TOST